{"denoms":[{"counts":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"17"},{"groupId":"BG003","value":"12"},{"groupId":"BG004","value":"52"}],"units":"Participants"}],"groups":[{"description":"Dose Level 1: Patients were administered Flavopiridol 30mg/m2 bolus followed by 30 mg/m2 4 hour infusion weekly for four weeks followed by two weeks without therapy for a total of 6 cycles","id":"BG000","title":"Dose Level 1"},{"description":"Dose Level 2: Patients were administered Flavopiridol 40mg/m2 bolus followed by 40 mg/m2 4 hour infusion weekly for four weeks followed by two weeks without therapy for a total of 6 cycles.","id":"BG001","title":"Dose Level 2"},{"description":"Dose Level 3: Patients were administered Flavopiridol dose level one scheduled for the first cycle. In absence of severe toxicity, dose level was escalated to 30mg/m2 bolus followed by 50 mg/m2 4 hour infusion for a total of 6 cycles","id":"BG002","title":"Dose Level 3"},{"description":"Dose Level 4: Patients were administered Flavopiridol dose level one scheduled for the first dose. In absence of severe toxicity, dose level was escalated to 30mg/m2 bolus followed by 50 mg/m2 4 hour infusion for a total of 6 cycles","id":"BG003","title":"Dose Level 4"},{"description":"Total of all reporting groups","id":"BG004","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"44","upperLimit":"84","value":"61.5"},{"groupId":"BG001","lowerLimit":"44","upperLimit":"62","value":"52"},{"groupId":"BG002","lowerLimit":"39","upperLimit":"69","value":"55"},{"groupId":"BG003","lowerLimit":"38","upperLimit":"75","value":"60"},{"groupId":"BG004","lowerLimit":"38","upperLimit":"84","value":"60"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"14"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"14"},{"groupId":"BG003","value":"9"},{"groupId":"BG004","value":"38"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"17"},{"groupId":"BG003","value":"12"},{"groupId":"BG004","value":"52"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"patients"}],"populationDescription":"52 unique patients due to 6 patients being"}